The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective

Purpose The purpose of the study was to characterize the utilization of medication against attention deficit hyperactivity disorder (ADHD) in Denmark between 1995 and 2011 from a national perspective, by using population-based prescription data. Methods National data on drug use in Denmark between 1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical pharmacology 2012-10, Vol.68 (10), p.1443-1450
Hauptverfasser: Pottegård, Anton, Bjerregaard, Bine Kjøller, Glintborg, Dorte, Hallas, Jesper, Moreno, Søren Ilsøe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1450
container_issue 10
container_start_page 1443
container_title European journal of clinical pharmacology
container_volume 68
creator Pottegård, Anton
Bjerregaard, Bine Kjøller
Glintborg, Dorte
Hallas, Jesper
Moreno, Søren Ilsøe
description Purpose The purpose of the study was to characterize the utilization of medication against attention deficit hyperactivity disorder (ADHD) in Denmark between 1995 and 2011 from a national perspective, by using population-based prescription data. Methods National data on drug use in Denmark between 1 January 1995 and 30 September 2011 were extracted from the Registry of Medicinal Product Statistics (RMPS). Drug utilization was characterized using descriptive statistics. Results A total of 1,085,090 prescriptions issued to 54,020 persons were identified. The incidence rate was stable in the last 3 years of the study period, and a slightly decreasing incidence rate and a stabilizing prevalence were observed towards the end of this period. The therapeutic intensity was 6.7 defined daily dose/person/day, with large regional differences that ranged from 64 to 145 % of the national average. Methylphenidate accounted for 92.6 % of DDDs used. The general practitioner (GP) rarely initiated treatment, although treatment initiation based on the GP’s advice increased with older age of the patient. Maintenance treatment was found to be distributed roughly equally between prescriber types. For methylphenidate, 1 % of users accounted for 6.1 % of the drug volume and 50 % of users accounted for 84.4 %. The data therefore do not suggest a high proportion of heavy users. Conclusion The findings of this analysis are mostly reassuring, with the data indicating a seemingly stagnant incidence and prevalence rate and lacking evidence of heavy users. However, the prescriber profile for incident users and the large regional variances raise concerns. It is therefore vital that the use of ADHD drugs is closely monitored.
doi_str_mv 10.1007/s00228-012-1265-y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1039203198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2756955101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-f95c433f9840ece293c1f0a419af690786776faebdf23e6494d70c80f48f14003</originalsourceid><addsrcrecordid>eNp1kUtP3TAQhS1UBLfAD-imslRV6iZ0_Ehid4foAyQkNnQdGWd8Mc11bm2nUlb96_g--hASK8vjb86MzyHkDYNzBtB-TACcqwoYrxhv6mo-IAsmRbmBZK_IAkCwqtEtHJPXKT0CsFqDOCLHnEshhdIL8vvuAemUkI6OrrD31mQ_BmqWxoeUqckZw7bSo_PWZ_owrzEam_0vn2fa-zTGHiP1gX7GsDLxxydqaB-n5VY15amfqYvjqlTDVtsMtCikNW408JQcOjMkPNufJ-T71y93l1fVze2368uLm8pK4LlyurZSCKeVBLTItbDMgZFMG9doaFXTto0zeN87LrCRWvYtWAVOKsdk8eGEfNjpruP4c8KUu5VPFofBBByn1DEQmhe7tCrou2fo4zjFsveWUqpVkvNCsR1l45hSRNetoy__nwvUbdLpdul0JZ1uk043l563e-Xpvpj9t-NPHAV4vwdMsmZw0QTr0z-uEaKpRV04vuNSeQpLjP-v-NL0J2m6qGs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038878422</pqid></control><display><type>article</type><title>The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Pottegård, Anton ; Bjerregaard, Bine Kjøller ; Glintborg, Dorte ; Hallas, Jesper ; Moreno, Søren Ilsøe</creator><creatorcontrib>Pottegård, Anton ; Bjerregaard, Bine Kjøller ; Glintborg, Dorte ; Hallas, Jesper ; Moreno, Søren Ilsøe</creatorcontrib><description>Purpose The purpose of the study was to characterize the utilization of medication against attention deficit hyperactivity disorder (ADHD) in Denmark between 1995 and 2011 from a national perspective, by using population-based prescription data. Methods National data on drug use in Denmark between 1 January 1995 and 30 September 2011 were extracted from the Registry of Medicinal Product Statistics (RMPS). Drug utilization was characterized using descriptive statistics. Results A total of 1,085,090 prescriptions issued to 54,020 persons were identified. The incidence rate was stable in the last 3 years of the study period, and a slightly decreasing incidence rate and a stabilizing prevalence were observed towards the end of this period. The therapeutic intensity was 6.7 defined daily dose/person/day, with large regional differences that ranged from 64 to 145 % of the national average. Methylphenidate accounted for 92.6 % of DDDs used. The general practitioner (GP) rarely initiated treatment, although treatment initiation based on the GP’s advice increased with older age of the patient. Maintenance treatment was found to be distributed roughly equally between prescriber types. For methylphenidate, 1 % of users accounted for 6.1 % of the drug volume and 50 % of users accounted for 84.4 %. The data therefore do not suggest a high proportion of heavy users. Conclusion The findings of this analysis are mostly reassuring, with the data indicating a seemingly stagnant incidence and prevalence rate and lacking evidence of heavy users. However, the prescriber profile for incident users and the large regional variances raise concerns. It is therefore vital that the use of ADHD drugs is closely monitored.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-012-1265-y</identifier><identifier>PMID: 22434389</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adolescent ; Adult ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Disorder with Hyperactivity - enzymology ; Attention deficit disorders. Hyperactivity ; Attention Deficit Hyperactivity Disorder ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Central Nervous System Stimulants - therapeutic use ; Child ; Child clinical studies ; Child, Preschool ; Denmark - epidemiology ; Drug Prescriptions - statistics &amp; numerical data ; Drug therapy ; Drug Utilization - statistics &amp; numerical data ; Epidemiology ; Female ; Humans ; Incidence ; Infant ; Infant, Newborn ; Male ; Medical sciences ; Methylphenidate - therapeutic use ; Middle Aged ; Pharmacoepidemiology ; Pharmacoepidemiology and Prescription ; Pharmacology ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Prevalence ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Young Adult</subject><ispartof>European journal of clinical pharmacology, 2012-10, Vol.68 (10), p.1443-1450</ispartof><rights>Springer-Verlag 2012</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-f95c433f9840ece293c1f0a419af690786776faebdf23e6494d70c80f48f14003</citedby><cites>FETCH-LOGICAL-c402t-f95c433f9840ece293c1f0a419af690786776faebdf23e6494d70c80f48f14003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-012-1265-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-012-1265-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26336535$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22434389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pottegård, Anton</creatorcontrib><creatorcontrib>Bjerregaard, Bine Kjøller</creatorcontrib><creatorcontrib>Glintborg, Dorte</creatorcontrib><creatorcontrib>Hallas, Jesper</creatorcontrib><creatorcontrib>Moreno, Søren Ilsøe</creatorcontrib><title>The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><description>Purpose The purpose of the study was to characterize the utilization of medication against attention deficit hyperactivity disorder (ADHD) in Denmark between 1995 and 2011 from a national perspective, by using population-based prescription data. Methods National data on drug use in Denmark between 1 January 1995 and 30 September 2011 were extracted from the Registry of Medicinal Product Statistics (RMPS). Drug utilization was characterized using descriptive statistics. Results A total of 1,085,090 prescriptions issued to 54,020 persons were identified. The incidence rate was stable in the last 3 years of the study period, and a slightly decreasing incidence rate and a stabilizing prevalence were observed towards the end of this period. The therapeutic intensity was 6.7 defined daily dose/person/day, with large regional differences that ranged from 64 to 145 % of the national average. Methylphenidate accounted for 92.6 % of DDDs used. The general practitioner (GP) rarely initiated treatment, although treatment initiation based on the GP’s advice increased with older age of the patient. Maintenance treatment was found to be distributed roughly equally between prescriber types. For methylphenidate, 1 % of users accounted for 6.1 % of the drug volume and 50 % of users accounted for 84.4 %. The data therefore do not suggest a high proportion of heavy users. Conclusion The findings of this analysis are mostly reassuring, with the data indicating a seemingly stagnant incidence and prevalence rate and lacking evidence of heavy users. However, the prescriber profile for incident users and the large regional variances raise concerns. It is therefore vital that the use of ADHD drugs is closely monitored.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - enzymology</subject><subject>Attention deficit disorders. Hyperactivity</subject><subject>Attention Deficit Hyperactivity Disorder</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Central Nervous System Stimulants - therapeutic use</subject><subject>Child</subject><subject>Child clinical studies</subject><subject>Child, Preschool</subject><subject>Denmark - epidemiology</subject><subject>Drug Prescriptions - statistics &amp; numerical data</subject><subject>Drug therapy</subject><subject>Drug Utilization - statistics &amp; numerical data</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylphenidate - therapeutic use</subject><subject>Middle Aged</subject><subject>Pharmacoepidemiology</subject><subject>Pharmacoepidemiology and Prescription</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Prevalence</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Young Adult</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUtP3TAQhS1UBLfAD-imslRV6iZ0_Ehid4foAyQkNnQdGWd8Mc11bm2nUlb96_g--hASK8vjb86MzyHkDYNzBtB-TACcqwoYrxhv6mo-IAsmRbmBZK_IAkCwqtEtHJPXKT0CsFqDOCLHnEshhdIL8vvuAemUkI6OrrD31mQ_BmqWxoeUqckZw7bSo_PWZ_owrzEam_0vn2fa-zTGHiP1gX7GsDLxxydqaB-n5VY15amfqYvjqlTDVtsMtCikNW408JQcOjMkPNufJ-T71y93l1fVze2368uLm8pK4LlyurZSCKeVBLTItbDMgZFMG9doaFXTto0zeN87LrCRWvYtWAVOKsdk8eGEfNjpruP4c8KUu5VPFofBBByn1DEQmhe7tCrou2fo4zjFsveWUqpVkvNCsR1l45hSRNetoy__nwvUbdLpdul0JZ1uk043l563e-Xpvpj9t-NPHAV4vwdMsmZw0QTr0z-uEaKpRV04vuNSeQpLjP-v-NL0J2m6qGs</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Pottegård, Anton</creator><creator>Bjerregaard, Bine Kjøller</creator><creator>Glintborg, Dorte</creator><creator>Hallas, Jesper</creator><creator>Moreno, Søren Ilsøe</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective</title><author>Pottegård, Anton ; Bjerregaard, Bine Kjøller ; Glintborg, Dorte ; Hallas, Jesper ; Moreno, Søren Ilsøe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-f95c433f9840ece293c1f0a419af690786776faebdf23e6494d70c80f48f14003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - enzymology</topic><topic>Attention deficit disorders. Hyperactivity</topic><topic>Attention Deficit Hyperactivity Disorder</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Central Nervous System Stimulants - therapeutic use</topic><topic>Child</topic><topic>Child clinical studies</topic><topic>Child, Preschool</topic><topic>Denmark - epidemiology</topic><topic>Drug Prescriptions - statistics &amp; numerical data</topic><topic>Drug therapy</topic><topic>Drug Utilization - statistics &amp; numerical data</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylphenidate - therapeutic use</topic><topic>Middle Aged</topic><topic>Pharmacoepidemiology</topic><topic>Pharmacoepidemiology and Prescription</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Prevalence</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pottegård, Anton</creatorcontrib><creatorcontrib>Bjerregaard, Bine Kjøller</creatorcontrib><creatorcontrib>Glintborg, Dorte</creatorcontrib><creatorcontrib>Hallas, Jesper</creatorcontrib><creatorcontrib>Moreno, Søren Ilsøe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Proquest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pottegård, Anton</au><au>Bjerregaard, Bine Kjøller</au><au>Glintborg, Dorte</au><au>Hallas, Jesper</au><au>Moreno, Søren Ilsøe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>68</volume><issue>10</issue><spage>1443</spage><epage>1450</epage><pages>1443-1450</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Purpose The purpose of the study was to characterize the utilization of medication against attention deficit hyperactivity disorder (ADHD) in Denmark between 1995 and 2011 from a national perspective, by using population-based prescription data. Methods National data on drug use in Denmark between 1 January 1995 and 30 September 2011 were extracted from the Registry of Medicinal Product Statistics (RMPS). Drug utilization was characterized using descriptive statistics. Results A total of 1,085,090 prescriptions issued to 54,020 persons were identified. The incidence rate was stable in the last 3 years of the study period, and a slightly decreasing incidence rate and a stabilizing prevalence were observed towards the end of this period. The therapeutic intensity was 6.7 defined daily dose/person/day, with large regional differences that ranged from 64 to 145 % of the national average. Methylphenidate accounted for 92.6 % of DDDs used. The general practitioner (GP) rarely initiated treatment, although treatment initiation based on the GP’s advice increased with older age of the patient. Maintenance treatment was found to be distributed roughly equally between prescriber types. For methylphenidate, 1 % of users accounted for 6.1 % of the drug volume and 50 % of users accounted for 84.4 %. The data therefore do not suggest a high proportion of heavy users. Conclusion The findings of this analysis are mostly reassuring, with the data indicating a seemingly stagnant incidence and prevalence rate and lacking evidence of heavy users. However, the prescriber profile for incident users and the large regional variances raise concerns. It is therefore vital that the use of ADHD drugs is closely monitored.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22434389</pmid><doi>10.1007/s00228-012-1265-y</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 2012-10, Vol.68 (10), p.1443-1450
issn 0031-6970
1432-1041
language eng
recordid cdi_proquest_miscellaneous_1039203198
source MEDLINE; SpringerNature Journals
subjects Adolescent
Adult
Attention Deficit Disorder with Hyperactivity - drug therapy
Attention Deficit Disorder with Hyperactivity - enzymology
Attention deficit disorders. Hyperactivity
Attention Deficit Hyperactivity Disorder
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Central Nervous System Stimulants - therapeutic use
Child
Child clinical studies
Child, Preschool
Denmark - epidemiology
Drug Prescriptions - statistics & numerical data
Drug therapy
Drug Utilization - statistics & numerical data
Epidemiology
Female
Humans
Incidence
Infant
Infant, Newborn
Male
Medical sciences
Methylphenidate - therapeutic use
Middle Aged
Pharmacoepidemiology
Pharmacoepidemiology and Prescription
Pharmacology
Pharmacology. Drug treatments
Pharmacology/Toxicology
Prevalence
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Young Adult
title The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T17%3A35%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20medication%20against%20attention%20deficit%20hyperactivity%20disorder%20in%20Denmark:%20a%20drug%20use%20study%20from%20a%20national%20perspective&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Potteg%C3%A5rd,%20Anton&rft.date=2012-10-01&rft.volume=68&rft.issue=10&rft.spage=1443&rft.epage=1450&rft.pages=1443-1450&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-012-1265-y&rft_dat=%3Cproquest_cross%3E2756955101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1038878422&rft_id=info:pmid/22434389&rfr_iscdi=true